INMB - NASDAQ
INmune Bio, Inc.
$1.89
-1.3%INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
At a Glance
Live Snapshotinmb
Net Cash Provided by Financing Activities
Last Annual Value
18.21M
3-Year CAGR
-43%
5-Year CAGR
8%
10-Year CAGR
90%
INmune Bio, Inc. Competitors Analysis of Net Cash Provided by Financing Activities
| Company | Net Cash Provided by Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
INmune Bio, Inc. NASDAQ:INMB | 18.21M | N/A | -28.3% | 44.8% | |
 Aligos Therapeutics, Inc. NASDAQ:ALGS | 101.64M | 4.8% | 5.3% | N/A | |
 PDS Biotechnology Corporation NASDAQ:PDSB | 12.77B | 820.5% | 204.4% | 106.4% | |
 X4 Pharmaceuticals, Inc. NASDAQ:XFOR | 238.63M | 39.2% | 26.3% | 29.4% | |
 Mersana Therapeutics, Inc. NASDAQ:MRSN | 4.09M | -64.9% | -42.2% | -23.3% | |
 OnKure Therapeutics, Inc. NASDAQ:OKUR | 163.00K | -85.5% | -73.8% | N/A | |
 CEL-SCI Corporation AMEX:CVM | 19.51M | 60.8% | -18.6% | -0.4% |
INmune Bio, Inc. Fair Value Envelope
Related Guides
Continue your INMB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.